CEACAM5 and cholangiocarcinoma: As the clinically nonspecific marker, carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) are either individually or combinedly used for CCA diagnosis and prognosis with variable sensitivity and specificity [2,3,4,5].